These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3244179)

  • 1. [Clinical evaluation of measurement of plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen in various liver disease].
    Yanagisawa N; Sugaya H; Hisauchi T; Harada T
    Nihon Shokakibyo Gakkai Zasshi; 1988 Dec; 85(12):2601-9. PubMed ID: 3244179
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serial changes in protein C, antithrombin III, alpha 2-plasmin inhibitor, plasminogen and von Willebrand factor during the course of disseminated intravascular coagulation (DIC)].
    Takahashi H; Hanano M; Takizawa S; Tatewaki W; Fuse I; Satoh K; Wada K; Shibata A
    Rinsho Ketsueki; 1988 Mar; 29(3):336-43. PubMed ID: 3260969
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases.
    Ito K; Niwa M; Kawada T; Tanaka Y
    Tokai J Exp Clin Med; 1986 Nov; 11(5):345-52. PubMed ID: 3672563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum antithrombin III and alpha-2-antiplasmin concentration in patients with lung carcinoma.
    Dabrowska M; Prokopowicz J; Kemona H; Kretowska J; Kulik S; Głuszczak M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):641-6. PubMed ID: 2465244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of fibrinolytic system, especially that of alpha 2 plasmin inhibitor deficient patient.
    Sakata Y
    Nihon Ketsueki Gakkai Zasshi; 1981 Dec; 44(7):1506-12. PubMed ID: 7342652
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):75-6. PubMed ID: 8756735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
    McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
    Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levels of antithrombin III and alpha 2-plasmin inhibitor in bone marrow aspirate].
    Tsurumi N; Hayashi H; Ishimaru F; Fujita T; Takai Y; Tsuda T; Kimura I
    Rinsho Ketsueki; 1988 Aug; 29(8):1207-13. PubMed ID: 3204671
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between antithrombin III, antiplasmin and plasma lipids in a healthy population.
    Scarabin PY; Bara L; Jacqueson A
    Thromb Haemost; 1983 Feb; 49(1):62. PubMed ID: 6845274
    [No Abstract]   [Full Text] [Related]  

  • 11. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
    Gram J; Munkvad S; Leebeek FW; Kluft C; Jespersen J
    Coron Artery Dis; 1993 Apr; 4(4):371-7. PubMed ID: 8261210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian rhythms of fibrinogen antithrombin III and plasminogen in chronic liver diseases of increasing severity.
    Pasqualetti P; Festuccia V; Acitelli P; Natali L; Collacciani A; Casale R
    Haemostasis; 1997; 27(3):140-8. PubMed ID: 9306131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in protein C inhibitor in disseminated intravascular coagulation: relationship with heparin cofactor II and alpha 2-plasmin inhibitor].
    Kazama Y; Takahashi K; Oguma Y; Sakuragawa N
    Rinsho Ketsueki; 1988 Mar; 29(3):344-8. PubMed ID: 3398266
    [No Abstract]   [Full Text] [Related]  

  • 14. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
    Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
    Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proteolytic activity in liver transplant rejection.
    Scholz T; Gallimore MJ; Bäckman L; Mathisen O; Bergan A; Klintmalm GB; Aasen AO
    Transpl Int; 1999; 12(2):100-7. PubMed ID: 10363591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation.
    Asakura H; Ontachi Y; Mizutani T; Kato M; Ito T; Saito M; Morishita E; Yamazaki M; Suga Y; Miyamoto KI; Nakao S
    Blood Coagul Fibrinolysis; 2001 Jun; 12(4):275-81. PubMed ID: 11460011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood coagulation and fibrinolysis during normal pregnancy.
    van Wersch JW; Ubachs JM
    Eur J Clin Chem Clin Biochem; 1991 Jan; 29(1):45-50. PubMed ID: 1904779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
    Rodzynek JJ; Urbain D; Leautaud P; Wettendorff P; Delcourt A
    Gut; 1984 Oct; 25(10):1050-6. PubMed ID: 6479679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-antithrombin complex and alpha2-plasmin inhibitor-plasmin complex levels after cesarean section in normal pregnancies and pre-eclampsia.
    Hayashi M; Hamada Y; Ohkura T
    Int J Gynaecol Obstet; 2003 Aug; 82(2):213-6. PubMed ID: 12873784
    [No Abstract]   [Full Text] [Related]  

  • 20. [Primary nephrotic syndrome treated with urokinase--a report of 20 cases].
    Wang LS; Chen EH; Zhou XJ
    Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):356-9, 382. PubMed ID: 2582915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.